How to Value This Rally in Novavax Shares
Despite the market falling on Tuesday, Novavax bucked the trend and was up handily, after a Phase 2 breakthrough with its RSV candidate.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 253UBS Makes Big Changes to Quality Growth at a Reasonable Price Portfolio
A new research report from UBS makes an interesting switch in the Quality Growth At a Reasonable Price (Q-GARP) portfolio.
Why AbbVie Should Be Worth 25% More
Independent research firm Argus has maintained its Buy rating and its $85.00 price target on AbbVie.
Is Cannabis Biotech Zynerba the Hottest Post-IPO of 2015?
ThinkstockZynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) had a solid run on Monday following the prior week’s initial public offering. The problem is that this deal was so small, and it came out during a serious…
Cancer Genetics to Acquire Assets of Response Genetics
Response Genetics has executed an asset purchase agreement with Cancer Genetics as a "stalking horse" bidder to potentially acquire all of the company's assets.
2 Analysts Continue to Like Shire-Baxalta Deal Pursuit
Baxalta has not been public as a standalone entity very long at all, when you consider that Shire is now interested in it.
Massive Additional Gains in Aquinox Driven by Large Shareholder Stake
It is day two of the massive rally of Aquinox Pharmaceuticals, and the stock is continuing to push higher.
MannKind Cheered Despite Lower Afrezza Shipments
MannKind reported a smaller than expected second-quarter net loss before the markets opened on Monday.
3 Large Biotech Stocks to Buy Despite Higher Interest Rates Coming
Merrill Lynch has looked at large cap biotech leaders and how interest rate increases may play a part in stock performance.
Janney Sees IBM and Merge Healthcare as Inconsequential
ThinkstockInternational Business Machines Corp. (NYSE: IBM) announced a small acquisition of Merge Healthcare (NASDAQ: MRGE) this week. The firm Janney Capital Markets sees this close to the way 24/7 Wall St. sees it. The…
Key Analyst Sees Mylan as a Value Play
ThinkstockMylan N.V. (NASDAQ: MYL) is considered a serious value play in the health care sector by a key analyst. Argus has a Buy rating for the company but reduced its price target to $65,…
DepoMed Fires Back at Horizon Pharma
Shots were fired again on the Horizon Pharma and DepoMed merger front. However it was DepoMed this time pushing back.
Can Aquinox Sustain Its Massive Rally?
Aquinox Pharmaceuticals made waves in the market Friday morning, with shares up over 200%, after it announced results from a Phase 2 trial.
5 Big FDA Decisions Expected in August
24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of August and added some color.
4 Large Cap Pharmaceutical Stocks to Buy on Strong Health Care Trends
24/7 Wall St. screened the Merrill Lynch health care universe and found four pharmaceutical stocks rated Buy with outstanding short-term and long-term potential.